Q&A Genmab 2021-03-23

	23/3 17:03 af troldmanden	Hi Jan. I have a question regarding HexaCD38. Would that molecule still need HALO?
	23/3 17:06 af Jan Van de Winkel	It is too early to comment here. Preclinically HexaBody-CD38 is far more potent than daratumumab and it depends on its clinical potency whether one would need high amounts of antibody for therapy in man. So we have to await data before we can say more about the need for a co-formulation.
	23/3 17:06 af soniarao2008	Can you discuss epcoritamab developments? When can we next expect data and filing? What indication would the first filing be in?
	23/3 17:08 af Jan Van de Winkel	The development program for epco will expand significantly during 2021. We will comment on it in detail, once new trials appear on ct.gov. We also expect updated data from epco clinical evaluations during 2021 and will inform you on the timing once decided. 2022 would be the absolute fastest time for a filing.
	23/3 17:08 af rsharma	When can we expect data updates on CEPHEUS? Will it be filed to regulators based on MRD- or will it require secondary endpoint analyses?
	23/3 17:09 af Jan Van de Winkel	We currently anticipate data for Cepheus in 2021 and Janssen will determine what data will be used for potential filing.
	23/3 17:10 af rsharma	Could you please discuss the progress of CASSIOPEIA Part 2 filing?
	23/3 17:11 af Jan Van de Winkel	It is up to Janssen to message on CASSIOPEIA part 2 filing.
	23/3 17:11 af GeorgeBest	You have often mentioned the unique robottic technology which gives you an advantage compared to Roche and others when developing new duobody candidates. Why can‘t competitors copy that process?
	23/3 17:12 af Jan Van de Winkel	This is related to the DuoBody platform, which is patent protected by Genmab.
	23/3 17:12 af Helge Larsen/PI-redaktør	And now to the last question.
	23/3 17:12 af GeorgeBest	When do you expect the first candidates from collaboration with CureVac, Immatics or Blink moving into the clinic?
	23/3 17:13 af Jan Van de Winkel	It is too early to provide timelines. We will only message specific timelines once a product candidate is slotted for introduction into the clinic..
	23/3 17:14 af Jan Van de Winkel	Genmab intends to bring one or two new products into the clinic each year. At present our entire product pipeline is built up of novel next-generation antibody therapeutics.
	23/3 17:15 af Helge Larsen/PI-redaktør	Thank you for joining us and thank you for the many fullfilling answers to our questions. We look forward to seeing you back here on ProInvestor.com after Q1.
	23/3 17:15 af Jan Van de Winkel	Thank you for a great exchange of information. Looking forward to chat after Q1.
	23/3 17:16 af Helge Larsen/PI-redaktør	This session has ended.